Delayed Graft Function Clinical Trial
Official title:
CliniMACS® CD34+ Reagent System for Expanded Access Use
CliniMACs is an investigational device used to select and enrich stem cells. The device will select the stem cells with CD34+ protein. The participant will be infused with the CD34+ selected cells in the hopes that it will help the participant engraft. Engraftment is when transplanted stem cells resume production of healthy blood cells.
- After the screening procedures confirm that the participant is eligible to participate
in the research study: If the participant takes part in this research study, the
participant (and their donor) will have the following tests and procedures:
- Donor Graft Collection: The participant's cell donor will undergo stem cell collection.
The cells collected will be sent to the laboratory for processing.
- Donor Graft Processing: In the laboratory the CliniMACS device will be used to separate
the CD34+ stem cells from the other types of cells in the graft. After completing the
necessary safety tests, the CD34+ selected donor graft will be ready for
administration.
- Donor Graft Infusion: The CD34+ selected donor graft will be infused through an
intravenous (I.V.) catheter. The day of this infusion is called Day 0.
- Follow-Up Visits: Approximately 3, 6 and 12 months after the donor graft infusion, the
participant will return to clinic for follow-up visits. At each of the visits, the
participant will have a physical exam and asked questions about your general health.
The participant will also have routine blood tests performed (approximately 1
tablespoon of blood).
- At times more cells are collected from a donation than are needed to do the
transplantation. If your physician determines that it is preferable to administer a
dose of cells that is less than the complete collection, the extra cells may be frozen
and stored in our freezers for the participant's future use. If the cell counts do not
improve, the participant will be given the remaining cells through an intravenous
(I.V.) catheter.
;
N/A
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT02312115 -
Delayed Renal Allograft Function and Furosemide Treatment
|
Phase 2 | |
| Completed |
NCT02134314 -
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
|
Phase 1/Phase 2 | |
| Completed |
NCT02346968 -
Evaluation of CAF22 After Renal Transplantation
|
||
| Completed |
NCT01794663 -
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
|
Phase 2 | |
| Completed |
NCT00298181 -
YSPSL for Prevention of Delayed Graft Function Part A
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05166460 -
Novel Cooling Device for the Elimination of Warm Ischemia During Renal Transplantation
|
N/A | |
| Recruiting |
NCT03071536 -
Furosemide Stress Test Predicting Early Graft Function in Kidney Transplantation
|
N/A | |
| Not yet recruiting |
NCT05513807 -
Graft Acute Kidney Injury: Vitamin B3 to Facilitate Renal Recovery In the Early Life of a Transplant
|
Phase 3 | |
| Recruiting |
NCT04005469 -
Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation
|
Phase 1/Phase 2 | |
| Completed |
NCT01848249 -
Deceased Donor Biomarkers and Recipient Outcomes
|
||
| Active, not recruiting |
NCT02474667 -
Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney
|
Phase 3 | |
| Terminated |
NCT00217152 -
A Kidney Transplant Study to Look at the Effects of Taking Fixed Doses of CellCept Versus Taking Doses of CellCept Based on the Concentration of CellCept in the Blood When Taking Full or Reduced Dose Calcineurin Inhibitors
|
Phase 4 | |
| Recruiting |
NCT05430620 -
Intermittent Versus Continuous Surface O2 During HMP of DCD Kidneys
|
Phase 3 | |
| Completed |
NCT03864926 -
Envarsus in Delayed Graft Function (E-DGF)
|
Phase 4 | |
| Recruiting |
NCT06367205 -
Norepinephrine Infusion Combined With Goal-directed Fluid Therapy in Patients Undergoing Kidney Transplantations
|
N/A | |
| Completed |
NCT02610296 -
QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant
|
Phase 3 | |
| Active, not recruiting |
NCT02568696 -
Intra-graft Coagulation Events in Clinical Renal Transplantation and Delayed Graft Function
|
||
| Recruiting |
NCT01837043 -
Early Conversion From CNI to Belatacept in Renal Transplant Recipients With Delayed and Slow Graft Function
|
Phase 2 | |
| Terminated |
NCT01878786 -
A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT01395719 -
Context - Remote Ischemic Conditioning in Renal Transplantation - Effect on Immediate and Extended Kidney Graft Function
|
N/A |